Ignite Creation Date:
2025-12-24 @ 7:01 PM
Ignite Modification Date:
2026-06-23 @ 10:15 PM
Study NCT ID:
NCT06941857
Status:
RECRUITING
Last Update Posted:
2025-12-03
First Post:
2025-04-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pancreatic Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Nivolumab | View |
| None | Ipilimumab | View |
| None | NC410 (NextCure LAIR-2 (Leukocyte-Associated Immunoglobulin-like Receptor-2) fusion protein) | View |
| None | Oxaliplatin | View |
| None | Irinotecan | View |
| None | Folinic Acid | View |
| None | 5-Fluorouracil | View |
| None | Folfirinox | View |
| None | Immunotherapy | View |
| None | Anti-PD-1 (anti-check point inhibitor) | View |
| None | PD-L1 (check point inhibitor) | View |
| None | Anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) | View |
| None | Metastatic Pancreatic Cancer | View |
| None | Pancreatic Cancer | View |
| None | Pancreatic Ductal Adenocarcinoma (PDAC) | View |
| None | Carcinoma | View |
| None | Pancreas | View |